BMS-243117 is a potent, and selective benzothiazole based p56Lck inhibitor with an IC50 of 4 nM. BMS-243117 inhibits anti-CD3/anti-CD28 induced PBL (human peripheral blood T-cells) proliferation with an IC50 of 1.1 μM. BMS-243117 binds in an extended conformation to the ATP-binding site of Lck[1].
[1] Jagabandhu Das, et al. Molecular design, synthesis, and structure-Activity relationships leading to the potent and selective p56(lck) inhibitor BMS-243117. Bioorg Med Chem Lett. 2003 Jul 7;13(13):2145-9. DOI:10.1016/s0960-894x(03)00380-9